Dr Reddy's Laboratories plans to resume semaglutide supplies from November after resolving semaglutide API scale-up issues, guiding 6 to 7 million units across 10 markets in Q3 and Q4 with Canada contributing the majority of volumes.

Dr. Reddy's Laboratories reported Q2 FY27 net profit of Rs 925 crore, down 36% from Rs 1,437 crore a year earlier due to a high base from generic Revlimid sales, but up 109% sequentially from Rs 444 crore as the Rs 240-crore semaglutide provision eased, with revenue at Rs 8,671 crore and EBITDA margin recovering to 20.6%.

Dr Reddy's Laboratories has launched two new generic semaglutide brands, Obeda Pro and Obeda Plus manufactured by Hetero Labs, after halting supplies of its original Obeda injection in July due to an impurity in the active ingredient. The company sold about 442,000 units of generic semaglutide through September in India, leading Sun Pharma, though analysts warned it risked losing share while Obeda supplies remain unavailable until November.

Dr Reddy's Laboratories received a maintained Buy rating and Rs 1,740 target price from Nomura ahead of its Q2FY27 results, with Nomura forecasting sequential growth and flagging potential 30% upside to FY28-FY29 earnings from biosimilar abatacept approval.

Dr Reddy's Laboratories received approval from the Drugs Controller General of India for Zytorvi in combination with cisplatin and paclitaxel as first-line treatment for advanced esophageal squamous cell carcinoma, marking its second approved indication in India beyond nasopharyngeal carcinoma.

Dr Reddy's Laboratories Limited saw strong mutual fund buying interest in September 2026, with 17 mutual funds buying against 4 selling, according to the Motilal Oswal Financial Services fund folio tracker.